Catalyst Dossier · compiled by CeliA 🧫
Grace Therapeutics, Inc. (GRCE)
Pharmaceutical Preparations · market cap $39M · as of 2026-07-17
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
4
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Grace Therapeutics (GRCE) is a micro-cap pharmaceutical company with a $40M market cap, 6 employees, and roughly 5.7 months of cash runway (~$17M). Its lead asset, GTX-104, is in Phase 3 for aneurysmal subarachnoid hemorrhage (aSAH), a severe and underserved neurological emergency; the company also holds a hypertriglyceridemia pipeline including CaPre in Phase 3.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| GTX-104 | Phase 3 | Aneurysmal Subarachnoid Hemorrhage (aSAH) |
| Lipid Lowering Medication | Phase 2 | Hypertriglyceridemia |
| CaPre | Phase 3 | Hypertriglyceridemia |
| CaPre (TM) | Phase 2 | Hypertriglyceridemia |
Price & technical context
3-month
-9.8%
6-month
-41.4%
12-month
-28.5%
52-wk range
$2.07–$5.13
vs 50-day MA
-9.3%
vs 200-day MA
-33.3%
Realized vol
82.2%
Max drawdown
-60.0%
Daily closes through 2026-08-10. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for GRCE (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.